Bristol Myers, 2seventy bio receive FDA approval for Abecma to treat multiple myeloma Bristol Myers Squibb (NYSE:BMY) stated on Friday that the corporate and 2seventy bio (NASDAQ:TSVT) obtained U.S. FDA approval … April 5,1:33 PM By Team News Nation Live In Markets